06:12 , Aug 10, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience reverse merging

Fertility company OvaScience Inc. (NASDAQ:OVAS) will reverse-merge with endocrine play Millendo Therapeutics Inc. (Ann Arbor, Mich.) in an all-stock deal. The resulting company will focus on developing Millendo's pipeline for orphan indications. New Enterprise Associates, Frazier...
19:45 , Jun 7, 2018 |  BC Innovations  |  Emerging Company Profile

Radio fusion

Fusion Pharmaceuticals Inc. is improving the safety of radiopharmaceuticals for cancer by using a proprietary linker to label antibodies with the radioisotope actinium-225. While the newco remains tight-lipped about the linker’s design, SVP of Business Development...
00:55 , Mar 16, 2018 |  BioCentury  |  Emerging Company Profile

Cirius safety

Cirius Therapeutics Inc. is developing a second-generation insulin sensitizer for non-alcoholic steatohepatitis that is designed to avoid cardiovascular symptoms and edema associated with first-generation agents. Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone from Takeda Pharmaceutical Co. Ltd....
18:28 , Dec 22, 2017 |  BioCentury  |  Finance

Modulating mechanism

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials...
00:11 , Dec 22, 2017 |  BC Week In Review  |  Financial News

Aptinyx raises $70M series B

On Dec. 18, neurology company Aptinyx Inc. (Evanston, Ill.) raised $70 million in an oversubscribed series B round led by new investor Bain Capital Life Sciences. New investors Adage Capital, Agent Capital, HBM Healthcare Investments,...
13:16 , Dec 18, 2017 |  BC Extra  |  Financial News

Aptinyx raises $70M series B

Aptinyx Inc. (Evanston, Ill.) raised $70 million in an oversubscribed series B round led by new investor Bain Capital Life Sciences. New investors Adage Capital, Agent Capital, HBM Healthcare Investments, Nan Fung Life Sciences, Partner...
04:17 , Dec 8, 2017 |  BC Week In Review  |  Financial News

Atox Bio raises $30M series F

On Dec. 4, Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners...
19:35 , Dec 4, 2017 |  BC Extra  |  Financial News

Atox Bio raises $30M series F

Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners and Asahi Kasei...
21:32 , Sep 29, 2017 |  BC Week In Review  |  Financial News

Fusion, IsoPlexis, Tempus announce venture financings

On Sept. 25, cancer company Fusion Pharmaceuticals Inc. (Hamilton, Ontario), single-cell analytics company IsoPlexis Corp. (Branford, Conn.) and health analytics company Tempus Labs Inc. (Chicago, Ill.) announced venture financings, raising over $100 million. Fusion raised $21...
23:38 , Sep 25, 2017 |  BC Extra  |  Financial News

Venture roundup: Fusion, IsoPlexis, Tempus

On Monday, cancer company Fusion Pharmaceuticals Inc. (Hamilton, Ontario), single-cell analytics company IsoPlexis Corp. (Branford, Conn.) and health analytics company Tempus Labs (Chicago, Ill.) announced venture financings, raising over $100 million. Fusion raised $21 million in...